The Best House On The Block Costs The Most: ISRG
In the world of robotic surgery, one company is both the undisputed leader and the most expensive name on the shelf, forcing investors to ask if operational brilliance is worth the high price of admission.
Intuitive Surgical (ISRG), the pioneer of robotic-assisted surgery, has seen its stock fall 27% over the last twelve months, now trading about 41% below its two-year high. For a company that essentially created its market, this raises a comparison shopper’s essential question: in a field with multiple competitors, why does Intuitive Surgical still command the highest price tag relative to its earnings, and is that premium truly earned?
Intuitive’s Premium is Built on Superior Performance.
By the numbers, Intuitive Surgical operates in a different league than its peers. Its operating margin of 31% is the highest in its competitive group, comfortably ahead of a giant like Johnson & Johnson at 27% and well above Medtronic’s 18.8%. This efficiency is paired with impressive growth; revenue expanded 21% over the last twelve months, outpacing most rivals.
Yet this performance comes at a cost. The stock trades at 40.8 times earnings, the richest valuation in the group. For context, another major competitor trades at a similar 39.8 times earnings, but Medtronic, a large and profitable device maker, is valued at just 23.2 times earnings. The market is clearly pricing Intuitive as the group’s leader, but the stock’s recent performance suggests investors are questioning the size of that lead.
| ISRG | MDT | JNJ | SYK | ZBH | GMED | |
|---|---|---|---|---|---|---|
| Market Cap ($ Bil) | 128.1 | 111.3 | 642.1 | 132.7 | 18.7 | 10.9 |
| PE Ratio | 40.8 | 23.2 | 30.5 | 39.8 | 24.5 | 18.6 |
| LTM Revenue Growth | 21% | 8.4% | 8.1% | 8.8% | 9.2% | 24% |
| LTM Operating Margin | 31% | 18.8% | 27% | 20% | 16.8% | 19.4% |
| 12M Stock Return | -27% | -3.5% | 62% | -13.2% | -0.8% | 48% |
But Can Strong Capital Sales Outrun Slowing Procedures?
The market’s high valuation is a bet on continued dominance and innovation, and the company is delivering on the capital front. Hospitals continue to invest heavily in Intuitive’s ecosystem, with the company placing 468 da Vinci systems in the most recent quarter, an 18% increase from the prior year. This demand is fueled by the new da Vinci 5 platform, signaling strong customer confidence.
However, the honest catch is a notable slowdown in the company’s core U.S. market. Management noted that U.S. da Vinci procedure growth came in at 12%, even as total worldwide da Vinci procedure growth remained strong at 15%. The company attributes this to “changes in patient coverage and premium dynamics” that are causing some patients to defer treatment. This raises some fundamental questions about the company’s path forward. A recent analysis, for instance, looks into the open questions on ISRG stock. If the slowdown is more than a temporary insurance issue and reflects a maturing market or rising competition, the premium valuation becomes much harder to justify. For investors looking for broader exposure to the health care sector without picking a single name, an ETF like VHT could be an alternative.
The Real Test is Whether New Systems Can Reignite Procedure Growth.
Intuitive Surgical’s operational excellence is not in doubt; its margins and growth rates are a testament to its leadership. The debate is whether the current stock price has already captured all of that value, especially with U.S. procedure growth showing signs of slowing. The bull case rests on the idea that strong sales of new, more capable systems will ultimately drive higher utilization and procedure volumes.
The decisive metric, then, is the one management has put on the table. The company is guiding for full-year 2026 worldwide da Vinci procedure growth to be within a range of 13.5% to 15.5% (with Q2’s 15% worldwide pace sitting near the upper end). Watching where the actual reported growth lands against this forecast will be the clearest signal of whether the U.S. slowdown was a blip or the beginning of a new, slower-growth reality for the king of robotic surgery.
To keep score on this group beyond today, our full peer-by-peer dashboards for ISRG track the whole lineup, metric by metric.
Even The Best Of The Group Is Still One Stock
Whichever name wins a peer comparison, buying it concentrates you in one company and one industry, and industries move together: when the group catches a cold, the best house on the block still sneezes.
The Trefis High Quality (HQ) Portfolio diversifies across roughly 30 quality names in different industries, selected on fundamentals and rebalanced with discipline, so no single group’s weather decides the outcome. It has a track record of outpacing a benchmark that combines three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Use the comparison to understand the stock; use the portfolio to own the market’s best.